NEUROCRINE BIOSCIENCES INC Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, employee stock purchase plan for the quarter ending 2020-12-31 was $0.00.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, employee stock purchase plan for the quarter ending 2020-09-30 was $2.90M, a 11.54% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, employee stock purchase plan for the quarter ending 2020-06-30 was $0.00.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, employee stock purchase plan for the quarter ending 2020-03-31 was $2.70M, a 8.00% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, employee stock purchase plan for fiscal 2020 was $5.60M, a 9.80% increase from fiscal 2019.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, employee stock purchase plan for fiscal 2019 was $5.10M.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05 | $5.60M 10-K · filed 2021-02-05 |
| 2020-09-30 | $2.90M 10-Q · filed 2020-11-09 | $5.60M derived: sum of 4 quarters · filed 2021-02-05 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $5.30M derived: sum of 4 quarters · filed 2021-02-05 |
| 2020-03-31 | $2.70M 10-Q · filed 2020-05-06 | $5.30M derived: sum of 4 quarters · filed 2021-02-05 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05 | $5.10M 10-K · filed 2021-02-05 |
| 2019-09-30 | $2.60M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | |
| 2019-03-31 | $2.50M 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |